

Synthetic Biology and Dual-Use Research of Concern

Dr. George Poste

Chief Scientist, Complex Adaptive Systems Initiative
and Regents Professor of Health Innovation

Arizona State University


george.poste@asu.edu

www.casi.asu.edu

**Presentation at the Fourth Annual Conference on
Governance of Emerging Technologies: Law, Policy and Ethics
Arizona State University • 25 May 2016**

Understanding Biological Organization: The Construction of Increasing Hierarchical Complexity and Mapping the Underlying Instructional Information


common genetic
(digital) code
in all life forms




tool box of
protein motifs
for combinatorial
assembly
("molecular lego")




assembly of
structurally and
functionally
diverse proteins



protein interactions
and nanoscale
intracellular
structures



molecular signaling
networks



cells and tissues



organs



organism

Digital Biology (Code) and Synthetic Biology (Construction)

- **reprogramming existing biological signaling pathways and networks**
- **program and assemble new biological functions and organisms based on knowledge of the ‘rule sets’ underlying hierarchical biological systems**
- **expanding the dimension of explored biospace**
 - **design, simulation and construction of novel functions/organisms with no known natural evolutionary counter part**
 - **novel biotic: abiotic combinations**
- **“directed evolution” and “accelerated evolution”**

Synthetic Biology

- emerging technology with myriad applications across diverse industrial sectors

Healthcare



Public Health




Agriculture




Functional Foods



Novel Materials



Textiles



Bioenergy and Biofuels



Industrial Enzymes



'Green' Mfg



Bio-remediation




Clean Water






Sensor Networks

Digital Programming of 3-D Fabrication and Assembly Using Non-Biological and Biological Substrates



Regenerative Medicine: Synthetic Biology and Tissue Engineering





DARPA

Less Inspiring Commercial Applications of Gene Editing Techniques



**Chinese
Mini-Pigs**



**Desired
Koi Coloration
Patterns**

Tech

OBJECT OF INTEREST



THE HOTTEST TECH IN SILICON VALLEY MADE THIS MEATBALL

WHAT: A "cultured" meatball from Memphis Meats, a San Francisco startup backed by almost \$3 million in venture funding. **FRESH MEAT:** The company makes its meat in a lab from the cells of cows, chickens, and pigs. One meatball takes three weeks to propagate in a steel tank. "It's not 'lab-grown' meat," says co-founder and CEO Uma Valeti. "It's like a meat brewery." **SQUARE MEAL:** Cells eat a diet of glucose, vitamins, and minerals to proliferate. "We create the conditions where the cells can grow freely." **TASTE TEST:** People who tested the cultured meatball couldn't tell that it was grown from cells.

"It has an undeniable and intense meat flavor. Our goal was not to be a vegetarian product." **CHECK, PLEASE:** There's a catch—one pound of ground beef costs Memphis Meats \$18,000 to grow. "We're trying to scale it up so that it's cost-effective." **HUNGER GAMES:** Startups making protein with fewer environmental and health risks are hot: Beyond Meat, which makes protein from plants, counts Bill Gates and two Twitter co-founders as investors; Gates also backed its rival, Impossible Foods. **NEXT COURSE:** Memphis Meats hopes to sell its product by 2021, Valeti says. "We're still in deep R&D." —Andrew Zaleski

Copyrighted material

"George Church is one of the most brilliant scientists in the world."

—STEVEN PINKER



REGENESIS

*How Synthetic Biology Will
Reinvent Nature and Ourselves*

GEORGE CHURCH AND ED REGIS

Copyrighted material



CONSERVATION,
DE-EXTINCTION AND THE
PRECARIOUS FUTURE
OF WILD THINGS

RESURRECTION SCIENCE

M. R. O'CONNOR

RESURRECTION SCIENCE



M. R. O'CONNOR

ST. MARTIN'S
PRESS

Synthetic Biology

- **technology acceleration and rapid diffusion**
- **major strategic national investments in enabling technologies**
- **rapid growth in corporate investment**
- **new wave of technologies with national security and military implications**
- **dramatic expansion in range of dual-use applications compared to historical dimensions of biosciences research**
- **eugenic implications**
 - **genome editing**
 - **synthetic human genomes**

Public Fears and Ethical Concerns Regarding Synthetic Biology and Engineered Modification and Design of Living Systems

- **‘unnatural’, ‘Playing God’, hubris**
- **risk from accident or errors**
- **malevolent use for military advantage and/or terrorism**
- **germline modification and eugenics**
- **social, inequity, discrimination and distributive justice**
- **undermine the life-machine distinction**

Dual-Use Research

- **generation of knowledge that can be used for beneficent or maleficent purposes**
- **traditional division between civilian applications versus military/terrorism uses**
- **new genetic technologies expand concept to include myriad civilian applications for modification of diverse species, including humans, and raise profound ethical, legal and social issues**

Dual-Use Research of Concern (DURC)


- **dual-use knowledge with the potential to cause profound societal disruptions based on misuse, accident or uncertain risks**

Dual-Use Research of Concern and the Rapid Pace of New Genetic Modification Technologies



**Mouse Pox
IL-4**



**Poliovirus
Synthesis**



**Influenza
GOF Virulence**



Synthetic Genomes

**CRISPR-CAS
Gene Editing**

Digital Genomes

DURC With Pathogenic Microorganisms



- increase virulence
- increase agent transmissibility/dissemination/persistence
- engineer resistance to countermeasures
- evasion of detection/diagnosis systems
- compromise host immunity and increase susceptibility
- alter host range and/or tissue tropism
- reconstitute eradicated or extinct agent
- de novo design of synthetic organisms with these traits

Therapeutic Oncolytic Viruses Designed to Circumvent Immune Detection

- Onco-Vex-GM-CSF (Amgen)
- Reolysin (Oncolytics Biotech)
- JX-594-Jennerex (Biotherapeutics)


Gain-of-Function (GOF) Research and DURC

- not all GOF research rises to level of dual-use research of concern (DURC)
 - routine use in study of gene function(s) in non-pathogenic context (e.g. cancer research)
- current narrow focus on microorganisms with major public health risks and pandemic potential
- new genetic technologies dramatically expand the potential for DURC
- synthetic organisms
- “beyond bugs”: modification of eukaryotes
- highly targeted “editing” of gene function/regulation in any organism/any biological network

Enabling Technologies in Synthetic Biology


- **genome sequencing (reading), synthesis (writing) and targeted modification (editing)**
- **assembly, delivery and integration of novel genes (targeting)**
- **designed regulation and control of complex genetic networks ('system states')**

Enabling Technologies in Synthetic Biology




- **accelerated directed evolution of molecular components/pathways with novel properties**
 - large scale biomanufacturing
 - integration into living systems
- **incorporation of non-natural molecular classes (xenobiology)**
 - expand genetic code/functional diversity of biological signaling pathways
 - xeno-nucleotides and nucleic acids (XNA)
 - non-canonical amino acids

Enabling Technologies in Synthetic Biology




- **comprehensive computational maps/simulation of biological signaling pathways and control systems**
 - **enhance accuracy of biological network engineering/redesign for increased predictability**
- **digital biology**

DIY Bio



- individuals not necessarily associated with scientific academic or industrial enterprises
- “biohacking”/“garage biology”
- “de-skilling”/“democratization” of biological research
- decreasing costs and automation
- more developed community in USA than elsewhere
- EU GMO regulations apply to GM activities irrespective of physical location or practitioner
- codes of conduct/on line training courses

Synthetic Biology, Genome Editing and National Security: The Ultimate Dual-Use Technology for Modification of Biological Systems?




**Technology Diffusion,
Automation,
Simplification and
Cost Reduction**



**New Oversight
Mechanisms
and International
Harmonization**

US Government Policy Frameworks for Managing Risk Associated With Life Sciences Research




US Policy Landscape for Bioweapons and Bioterrorism


- **Biological and Toxin Weapons Convention**
- **Biological Weapons Anti-Terrorism Act (Public Law 101-298, 1990)**
- **Antiterrorism and Effective Death Penalty Act (Public Laws 104-132, 1996)**
- **USA Patriot Act (Public Law 107-56, 2001)**
- **Public Health and Bioterrorism Preparedness and Response Act (Public Law 107-188, 2002)**
- **federal and institutional policies for oversight of dual-use research of concern (White House, 2012, 2015)**

Thinking “Beyond Bugs”

Understanding the Topology of Information Flow and Architecture of Control Networks in Complex Biological Systems



- Black Swans
- dislocations
- tipping points
- irreversible cascades
- phase shifts
- perturbations
- inflection points
- unintended consequences
- critical thresholds
- bifurcations
- trigger points



The Complexity of Dual-Use Issues

- **multifactorial, non-linear events and rude surprises**
- **deliberate misuse versus error/accident**
- **intent and risk spectrum**
- **capacity, cost and probability of successful translation**
- **ease of detection/mitigation/attribution**
- **oversight, regulation, compliance**
- **international harmonization**

Risk, Regulation and Responsibility

SAFETY OF GENETICALLY ENGINEERED FOODS

APPROACHES TO ASSESSING UNINTENDED HEALTH EFFECTS



NATIONAL RESEARCH COUNCIL AND INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMIES

POTENTIAL RISKS AND BENEFITS OF GAIN-OF-FUNCTION RESEARCH


Summary of a Workshop



NATIONAL RESEARCH COUNCIL AND INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMIES

GAIN-OF-FUNCTION RESEARCH

Summary of the Second Symposium
March 10–11, 2016



The National Academies of SCIENCES • ENGINEERING • MEDICINE

Implementation of the U.S. Government Policy for Institutional Oversight of Life Sciences DURC: Frequently Asked Questions

Prepared by the National Institutes of Health on behalf of the United States Government

September 2014

NUFFIELD COUNCIL ON BIOETHICS

BACKGROUND PAPER

Dual Use in Biology and Biomedicine

Dr Filippa Lentzos, Senior Research Fellow in the Department of Social Science, Health and Medicine, King's College London

November 2015

Note

The author was commissioned by the Nuffield Council on Bioethics to write this paper in order to inform the Council's discussions about possible future work on this topic. The paper is intended to provide an overview of key clinical, ethical, social, legal and policy issues, but is not intended to offer any conclusions or recommendations regarding future policy and practice. Any views expressed in the paper are the author's own and not those of the Nuffield Council on Bioethics.

THE DNA OF THE U.S. REGULATORY SYSTEM: ARE WE GETTING IT RIGHT FOR SYNTHETIC BIOLOGY?



October 2015

Synthetic BIOLOGY

W Wilson Center



Scientific Committee on Health and Environmental Risks
SCHER
Scientific Committee on Emerging and Newly Identified Health Risks
SCENIHR
Scientific Committee on Consumer Safety
SCCS

Opinion on
Synthetic Biology II
Risk assessment methodologies and safety aspects



The Scientific Committees adopted this Opinion:
The SCENIHR at their plenary on 28 April 2015, the SCHEER and the SCCS by written procedure on 4 May 2015



Emerging and Readily Available Technologies and National Security — A Framework for Addressing Ethical, Legal, and Societal Issues

NATIONAL RESEARCH COUNCIL AND NATIONAL ACADEMY OF ENGINEERING OF THE NATIONAL ACADEMIES



**Coordinated Framework for
Regulation of Biotechnology**

**Food and Drug Administration
Modernization Act**

Federal Food, Drug and Cosmetic Act

**Federal Insecticide,
Fungicide and Rodenticide Act**

**Toxic Substances
Control Act**

Plant Protection Act

National Environment Policy Act

Food Safety Modernization Act

Export Control Act

The Complexity of Risk-Benefit Assessment for DURC

- **multi-disciplinary, multi-dimensional**
- **evaluation in context of entire life cycle (from research to tangible utility/threat)**
- **diverse stakeholders**
 - **scientific, clinical, public health and military/security communities**
 - **social, behavioral and decision science**
 - **public and private sectors**
 - **general public**
- **oversight mechanisms**
 - **law, guidelines, best practices, codes-of-conduct**
 - **compliance, enforcement and penalties**
 - **moratoria and/or prohibition**

Risk, Restraint and Responsibility: Purported Claims By The Academic Research Community

- **intrinsic value of “knowledge”**
- **scientists are not responsible for harmful uses of their research (the gunmaker’s defense)**
- **individual scientists cannot affect the overall trajectory of a research field**
- **publication as deterrent to misuse**
- **publication as critical vehicle to inform countermeasure development**

Regulatory Oversight of Synthetic Biology Products

- **current biosafety/containment requirements**
- **current environmental release requirements**
- **modified organisms as biosensors**
 - **containment, release and classification as devices?**
- **modified endosymbiont organisms as probiotic/dysbiosis therapeutics**
 - **drug approval requirements?**
- **next-generation genetic and synthetic biology technologies?**
 - **gene drives, gene editing**
 - **synthetic organisms**

Evaluation of DURC

- from focus on method/process of production to risk assessment of end product, its properties and societal impact

Genetically-Designed Safeguard to Limit Survival of Modified and/or Fully Synthetic Organisms: 'Kill' and 'Suicide' Switches

- **auxotrophic dependency**
 - survival requires chemical(s) not available in natural environments
- **induced lethality**
 - two gene system in which activation of 'toxic' second gene silences the first gene and kills the organism
- **toxin-antitoxin pairs**
 - plasmid-borne toxic peptide neutralized by genome-encoded antitoxin
 - when both expressed the cell survives but plasmid transfer to another cell without anti-toxin results in toxin-mediated death of receiver cell



International Gene Synthesis Consortium

- **screening and reporting orders for potentially dangerous sequences**
 - **focus on select agents**
- **likely increasing irrelevance as a biosafety/surveillance tool**
 - **low cost of synthesis machines**
 - **digital genome computer codes bypass screening and surveillance tools**
 - **new gene editing tools makes any gene a target**


Game Changers

Gene Drives

Precision Gene Editing

Digital Genomes

Gene Drives Rapid Penetrance of New Traits




CRISPR-Cas and Precision Genome Editing

Using An Evolutionary Mechanism from 3-4 Billion Years Ago for 21st Century Genome Design


Change, Delete or Replace Genes in Any Living Species, Including Humans

Genome Editing



**Microbial CRISPR
Defense System
Against Viruses**



**CRISPR-Cas Guided Excision
and Insertion of New Genes**



CRISPR-cas9 and Precision Gene Editing



The Rapid Growth of a New Industry Supply Chain for CRISPR-Cas Gene Editing Services

Mirus The Transfection Experts

X2 for CRISPR

See the MIRUS CRISPR/Cas9 Transfection Guide www.mirusbio.com/X2000

TransIT-X2[®] Dynamic Delivery System

Now you can use the same transfection reagent for your CRISPR/Cas9 system. TransIT-X2[®] Dynamic Delivery System is a CRISPR/Cas9 system with an improved plasmid packaging that efficiently delivers CRISPR/Cas9 plasmids, such as gRNA and Cas9, into your cells.

The TransIT-X2[®] Dynamic Delivery System delivers CRISPR/Cas9 components in multiple formats:

1. gRNA: Active gRNA (gRNA) encoding 1-2 kb gRNA
2. gRNA: gRNA in CRISPR/Cas9
3. Protein: Active Cas9 gRNA complex

20 years of experience

www.mirusbio.com
Providing gene delivery solutions since 1998

CRISPR Plasmids

KNOCKOUT & ACTIVATION

CRISPR/Cas9
Knockout Plasmids
Knockout/Repair Plasmids
Knockout/Repair Plasmids
CRISPR/Cas9
Activation Plasmids
Knockout/Repair Plasmids

DELIVERED BY SCBT.COM

GE Healthcare

CRISPR

Dharmacon[®] reagents help you move forward. Faster.

Simplify your gene editing workflow with the Edit-R[™] CRISPR-Cas9 platform. Custom or pre-designed ready-to-use DNA and synthetic RNA reagents and/or you to modify multiple target sites per gene across lines or hundreds of genes - moving you closer to high-confidence results.

Functionality | Specificity | Validated protocols

www.gehealthcare.com/CRISPR

JUST IMAGINE

THE POSSIBILITIES WITH AUTOMATED CRISPR ANALYSIS


Fragment Analyzer[™] is the only automated instrument for the analysis of CRISPR/Cas9 gene-editing events. Automates your scientific discovery using a streamlined process for easy visualization of both individual and pooled gene modifications.

More at AATI-ON.COM

ADVANCED ANALYTICAL
imaging genetic diversity

Applications of Synthetic Biology in Healthcare:

Z Kis et al. (2015) J. Roy. Soc. Interface 12, 201410000



CRISPR-Cas Precision Gene Editing and Engineered Resistance to Viral Diseases




**susceptible to
African swine fever (ASV)**



**transfer ASV resistance
genes to domestic pigs**

CRISPR-Cas and Gene Editing to Design Pig Organs for Xenogeneic Transplantation to Humans



**122K Americans on
Waiting List for
Organ Transplants**



**Elimination of Pig
Genes That Trigger
Transplant Rejection**

CRISPR-Induced Mutation in MECP2 Gene in Macaques and Induction of Rett Syndrome/Autism Spectrum Disorder Models



Regulatory Review of Genome Editing

- **dramatic expansion of potential applications**
 - **microorganisms, plants, animals**
 - **human therapeutics**
- **advocacy that GMO-type oversight based on transgenic technology should not apply**
 - **use of naturally occurring gene modification and repair systems**
 - **homologous (precision) spatial localization of gene modification(s)**

Gene Editing of Humans





**Somatic Cell Modification and
Augmentation (non-heritable)**

**Germ Line Modification
Enhancement (heritable)**

**Very Different Ethical, Legal
and Social Implications**

Somatic Cell Gene Editing

- monogenic versus multigenic diseases
- ex vivo modification versus targeted in situ modification
- detection of off-target effects
- confirmation that germ line not modified inadvertently
- epistatic interactions and gene-environment interactions of modified gene(s)
- creation of new risk/susceptibilities
 - T cell CCR5 gene modification confers resistance to HIV but increases susceptibility to W. Nile virus infection



Editing the Human Germ Line: No Longer An Abstract Question

Research article

CRISPR/Cas9-mediated gene editing in human trippronuclear zygotes

Puping Liang¹, Yanwen Xu¹, Xiya Zhang¹, Chenhui Ding¹, Rui Huang¹, Zhen Zhang¹, Jie Lv¹, Xiaowei Xie¹, Yuxi Chen¹, Yujing Li¹, Ying Sun¹, Yaofu Bai¹, Zhou Songyang¹, Wen Ma¹, Canquan Zhou¹  and Junjiu Huang¹ 


(1) Guangdong Province Key Laboratory of Reproductive Medicine, the First Affiliated Hospital, and Key Laboratory of Gene Engineering of the Ministry of Education, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510275, China

 Canquan Zhou (Corresponding author)

Email: zhoucanquan@hotmail.com

 Junjiu Huang (Corresponding author)

Email: hjunjiu@mail.sysu.edu.cn



International Summit on Human Gene Editing: Washington, DC 1-3 December 2015



**“Today, we sense that we are close
to being able to alter human heredity.
Now we must face the questions that arise.
How, if at all, do we as a society
want to use this capability?”**


Dr. David Baltimore

Production of Autologous Germ Cells from Reprogrammed Somatic Cells



- production of oocytes, spermatids and spermatozoa from induced pluripotent stem cells (iPSCs)
- accomplished in mice and production of healthy offspring
- prospect of gene editing of iPSCs and subsequent induced differentiation of primordial germ cells
- critical safety concerns regarding genomic instability of iPSCs

Mitochondrial Replacement Therapy



From: M.J. Falk et al. (2016) NEJM 374, 1103

Germ Line Gene Editing



- heritable change
- complex ethical, social and legal issues
 - impact on future generations
 - moral status and rights of the unconsented embryo
- varied responses of patient advocacy groups affected by inherited disorders
 - “hell yes, do it” versus “let’s wait to see the technology mature”
- the lurking spectre of eugenics
 - social justice, equity, coercion
 - economic forces
 - who decides?

Medical Tourism


**Offshore Surrogate Mothers, Stem-Cell
Treatments and Organ Transplants**

**Market Precursors for Next Phase of
Customized Gene Edited Human Embryos?**

Democracy



(Re)Design



**“What rights do we
now hold (see)
as self-evident?”**

The Journey to the Anthropocene: The Long History of Technology-Enabled Human Augmentation

- **improved health, shelter, labor, education**
- **improved nutrition, clean water, sanitation, infrastructure**
- **transportation**
- **public policies and protection of individual rights**
- **advances in clinical medicine and therapeutics**
- **devices, implants, prostheses**
- **computing, connectivity and communication**
- **in vitro fertilization**
- **somatic cell gene therapy**

Arguments Against Bioenhancement

- **“ ‘Playing God’ or secular version as ‘altering the natural balance of nature’ ”**
- **subversion of human dignity by commodification of human traits and capabilities**
- **disruption/destruction of qualities that render us human**
- **inequitable access, prejudice and fragmentation of the species**
- **unknown and unintended consequences**

Arguments in Favor of Bioenhancement

- **limit human suffering**
- **intrinsic human drive in the Promethean quest for new knowledge, new capabilities and richer experiences**
- **next phase in the technological trajectory of human control of the natural world (the anthropocene)**
- **future evolution by Darwinian selection combined with purposeful design of desired new states**
- **who decides?, what is selected?, who has access?**

Secret Meeting Of Scientists To Discuss Creating Synthetic Human Genome Fuels Speculation

May 16, 2016 | by Josh L Davis



Scientists Talk Privately About Creating a Synthetic Human Genome

By ANDREW POLLACK MAY 13, 2016



Sixty trays can contain the entire human genome as 23,040 different fragments of cloned DNA. James King-Holmes/Science Source

Scale Matters!




Worldwide DNA Sequencing Capacity

- doubling every 9-12 months
- 35 Petabases/year (2015) $\equiv$ capacity for 250K human genomes
- Illumina X-10 sequencer instrument
 - 18,000 whole human genomes/year
- projected growth from petabyte to exabyte scale in a decade

Digital to Biological Conversion: The Next Phase in Biotechnology and Synthetic Biology

- **genome sequences are digital**
- **transmission of digital code(s) for distributed dissemination and production**
- **prototype instruments for fully automated integration of complex biological signaling pathways**
 - **gene sequence → digital code → gene synthesis → mRNA and gene expression → protein product**
- **geographic uncoupling of knowledge of source code from product manufacturing**

Technology Acceleration and Refinement



Big Biology and Biomedicine Meets Big Data

The Pending Zettabyte Era
1,000,000,000,000,000,000,000




**Integration of Large Scale,
Multi-Disciplinary Datasets**

- **limits to individual expertise**
- **limits to our multi-dimensionality**
- **limits to our sensory systems**
- **limits to our experiences and perceptions**
- **limits to our objective decision-making**

Technology Convergence and Synthetic Biology: Biology and Medicine Meet Engineering and Computing


**Modeling and Simulation of
Biological Networks**



**Automation/Miniaturization and
Robotic Production Suites**



**Exabyte and Zettabyte
Computing Scale**



**Advanced Computing,
New Analytical Tools and
Machine Intelligence**

“Digital Darwinism”

- a pending digital divide
- growing imbalance in sophistication of different end users and their ability to embrace data scale and complexity
- institutions unable to access and analyze large data sets will suffer ‘cognitive starvation’ and relegation to competitive irrelevance

Data Security



- data theft
- data corruption
- intellectual property
- ownership of personal genetic data
- genomic code as a target

Synthetic Biology, Genome Editing and Engineered Construction of Biological Circuits


digital biology:
“it from bits”



engineered
virulence



de novo
synthesis of organisms



targeted modification of any
biological circuit in any organ



mapping neural circuitry
brain – machine interfaces



accelerating technological
diffusion

New Genetic Modification Technologies and Regulatory Oversight

- **gene editing and gene drives represent an inflection point in genomic modification technologies**
- **technology is outpacing risk:benefit assessment and oversight mechanisms**
- **current regulations focus primarily on containment but new technologies are designed primarily for widespread use and dissemination**

Synthetic Biology and Dual-Use Research of Concern (DURC)

- **new classes of bioweapons and bioterrorism threat**
- **accident/error in manipulation of pathogens with pandemic potential**
- **generation of fully synthetic organism and introduction into natural ecosystems**
- **human germ line modification and eugenics**
- **engineered life forms and blurring the life-machine distinction**
- **social and distributive justice**
- **existential threats: real or imagined.**

Synthetic Biology and Dual-Use Research of Concern (DURC): Seeking Balance

- **risk:benefit**
- **safety and security**
- **hierarchical governance and oversight**
 - **codes of conduct, guidelines**
 - **regulation and legislation**
 - **moratoria and/or prohibition**
 - **international harmonization**
- **freedom of scientific enquiry and publication
versus prudent constraint**

Slides available @ <http://casi.asu.edu/>

